Exane BNP Paribas upgraded Equifax from Neutral to Outperform and set a new price target of $305.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $280.00 | Buy | BofA Securities |
| 4/4/2025 | $260.00 | Overweight → Equal Weight | Barclays |
| 3/20/2025 | $300.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/14/2025 | $265.00 | Outperform → Neutral | Exane BNP Paribas |
| 2/11/2025 | Buy → Hold | Argus | |
| 12/16/2024 | $305.00 | Neutral → Outperform | Exane BNP Paribas |
| 12/12/2024 | Outperform → Peer Perform | Wolfe Research | |
| 12/12/2024 | $275.00 → $320.00 | Equal-Weight → Overweight | Morgan Stanley |
4 - EQUIFAX INC (0000033185) (Issuer)
4 - EQUIFAX INC (0000033185) (Issuer)
4 - EQUIFAX INC (0000033185) (Issuer)